Back to Journals » International Journal of Nanomedicine » Volume 5

Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier

Authors Mori Y, Nakamura S, Kishimoto S, Kawakami M, Suzuki S, Matsui T, Ishihara M

Published 11 March 2010 Volume 2010:5 Pages 147—155

DOI https://doi.org/10.2147/IJN.S8692

Review by Single anonymous peer review

Peer reviewer comments 4



Yasutaka Mori1,3,4, Shingo Nakamura2, Satoko Kishimoto1, Mitsuyuki Kawakami4, Satoshi Suzuki4, Takemi Matsui4, Masayuki Ishihara1

1Research Institute, 2Department of Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan; 3Aeromedical Laboratory, Japan Air Self-Defense Force, Sayama, Saitama, Japan; 4Faculty of System Design, Tokyo Metropolitan University, Hino, Tokyo, Japan

Abstract: We produced low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as a carrier for heparin-binding growth factors, such as fibroblast growth factor-2 (FGF-2). A mixture of low-molecular-weight heparin (MW: about 5000 Da, 6.4 mg/mL) and protamine (MW: about 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (1–6 μm in diameter). In this study, diluted low-molecular-weight heparin solution in saline (0.32 mg/mL) mixed with diluted protamine (0.5 mg/mL) at a ratio at 7:3 (vol:vol) resulted in soluble nanoparticles (112.5 ± 46.1 nm in diameter). The generated NPs could be then stabilized by adding 2 mg/mL dextran (MW: 178-217 kDa) and remained soluble after lyophilization of dialyzed LMW-H/P NP solution. We then evaluated the capacity of LMW-H/P NPs to protect activity of FGF-2. Interaction between FGF-2 and LMW-H/P NPs substantially prolonged the biological half-life of FGF-2. Furthermore, FGF-2 molecules were protected from inactivation by heat and proteolysis in the presence of LMW-H/P NPs.

Keywords: polyelectrolyte complexes, nanoparticles, fibroblast growth factor-2, drug carrier

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.